Lukas Guenther

Endostart is a startup founded in 2018 for the development and manufacturing of a new generation medical devices for gastrointestinal endoscopy. Magnetic Balloon Technology has been developed to enhance endoscopes performances and enable endoscopists to easily achieve quality standards. Endostart has implemented a comprehensive quality management system according to ISO 13485. Endostart is supported by private investors, led by a highly professional team and an international Board of Directors.

Quobyte turns commodity servers into a Data Center File System. Based on latest distributed systems technology, Quobyte delivers linear scalability, full fault tolerance, and lights-out operations – so that you can focus on your business applications and stop worrying about your storage infrastructure.

Every day, we strive to help our customers find balance in their lives. Whether your focus is fitness, health, or balanced nutrition, our innovative products support individual health goals, offer practical solutions for optimal nutrient intake, and provide a platform and community for health-focused learning and sharing. Discover our core categories—SPORT, HEALTH, and FOOD—to achieve your daily balance. Become part of the nu3 community. Balance your health.

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

Quanta Dialysis Technologies is committed to making dialysis accessible to every patient in every setting with its SC+ hemodialysis system. As a portable device with performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. With a simple-to-use and intuitive user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients. Disclaimer: The SC+ Haemodialysis system is FDA-cleared for use on patients with acute and/or chronic renal failure when administered by a trained person in an acute or chronic care facility. It is not indicated for home or nocturnal use in the USA. CONTACT US Office / Business Enquiries: UK: 0-178-940-0043 US: 1-978-483-0669 Customer Care: UK: 0-808-164-2640 US: 1-800-590-1393

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne. The program combines 5 elements to help companies transition from science projects to scalable and financeable companies: - An emphasis on objective-setting, helping companies focus on what’s most important to their business - Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies - Technical advice from world-leading scientists, engineers, and economists - Hands-on support from top business students, who embed within the company to provide business support - Opportunities to raise capital, including angels and VCs from Europe and North America The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.

Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €4 billion under management. For more information, please visit: www.sofinnovapartners.com

MD Start is a fund, a team of entrepreneurs and an incubator combined, aimed at transforming innovative ideas into medical realities. Our mission is to incubate medical device innovations to the point where proof-of-principle in patients is demonstrated, allowing for interest from traditional investors and our continued funding. Our team operates the projects and new companies to bridge the gap between science and clinical experience. We source innovations that are too early for large corporate or venture investors. These inventions arise from clinicians all over the world who do not wish to become entrepreneurs Our ambition is to turn these breakthrough inventions into world-class medtech companies.

Endostart is a startup founded in 2018 for the development and manufacturing of a new generation medical devices for gastrointestinal endoscopy. Magnetic Balloon Technology has been developed to enhance endoscopes performances and enable endoscopists to easily achieve quality standards. Endostart has implemented a comprehensive quality management system according to ISO 13485. Endostart is supported by private investors, led by a highly professional team and an international Board of Directors.